The Study Of C-0301 Liposomes

Background:C-0301 is a kind of developing thrombus disaggregating prodrug belong to the prostaglandin family, It is converse from cyclopentane fatty series lateral chain prostaglandin and substituting group modified; remaining the characters of prostaglandin family such as vasodilation, inhibition of platelet aggregation and prevention of artherosclerosis. In addition, compare with the other prostaglandin family agent, it has been increased chemical stability and decreased the deactivation rate during passage through the lungs when administered systemically. With the development of the modern pharmacy, more and more methods have been used to encapsulate the active compound into a stable system and serve to clinic. In present, the injection of cyclodextrin inclusion complex and emulsion of prostaglandin family drugs associated with phospholipid microspheres are emphases in our country. Liposomes, as a carrier of anti-thrombus medication , which may alter drug transport, enhance the targeting pharmacological effects of the drugs and increase the half-life of the parent compound, advance pharmacological effects, decrease the dosage and avoid toxicity and adverse effect. In this article, the purpose of this study is to incorporate C-0301 into liposome in order to enhance the stability and therapy activity of this preparation and make a theory base for developing new drugs.Objective:1. To develop good liposomal C-0301 (Lipo-C-0301) with high entrapment efficiency and stable drug concentration in order to develop a new therapeutic preparation.2. To establish the quality standard for determining C-0301 in liposomal C-0301 .3. To evaluate the stability of Lipo-C-0301 at several different conditions, and to direct the store condition and formulation screening for the next research4. To investigate the dissolution properties in vitro of liposomal C-03015. To study the protective effect of Lipo-C-0301 on myocardial ischemia-reperfusion injury in rats...